NCT03661307 2026-01-12
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
Clinical Trials
24 trialsNCT04657081 2025-12-08
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
Taiho Oncology, Inc.
Phase 1/2 Active not recruiting
NCT05918055 2025-12-02
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT06928662 2025-11-06
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06129734 2025-08-26
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04086264 2025-08-14
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
AbbVie
Phase 1/2 Active not recruiting
NCT02257138 2025-06-08
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04113616 2024-03-22
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Kartos Therapeutics, Inc.
Phase 1/2 Terminated
NCT02632721 2024-03-19
A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Boehringer Ingelheim
Phase 1/2 Completed
NCT04485052 2023-10-23
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Suspended
NCT02878785 2023-03-29
1565GCC
University of Maryland, Baltimore
Phase 1/2 Completed
NCT03303339 2023-02-27
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
Cardiff Oncology
Phase 1/2 Completed
NCT02996474 2022-12-28
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02109744 2022-07-05
AML
University of Rochester
Phase 1/2 Completed
NCT01893320 2022-02-09
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03113071 2021-03-16
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT04493099 2020-11-12
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT02921061 2020-03-17
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01211457 2019-07-16
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
NCT01794702 2019-05-30
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01729845 2019-02-07
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00002831 2018-10-26
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00691938 2016-10-13
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
Washington University School of Medicine
Phase 1/2 Completed
NCT00002832 2012-07-30
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed